Genmab A/SGMABNASDAQ
Loading
EBITDA Margin Over TimeContracting
Percentile Rank21
3Y CAGR-11.2%
5Y CAGR-10.2%
Year-over-Year Change
EBITDA as a percentage of revenue
3Y CAGR
-11.2%/yr
vs -2.6%/yr prior
5Y CAGR
-10.2%/yr
Consistent
Acceleration
-8.6pp
Decelerating
Percentile
P21
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 35.51% | -21.2% |
| 2024 | 45.05% | +24.8% |
| 2023 | 36.10% | -28.7% |
| 2022 | 50.64% | +2.0% |
| 2021 | 49.67% | -18.5% |
| 2020 | 60.92% | +8.8% |
| 2019 | 56.00% | -0.3% |
| 2018 | 56.20% | -10.7% |
| 2017 | 62.91% | -2.5% |
| 2016 | 64.50% | - |